Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This multicenter study aims to evaluate the predictive value of tumor microenvironment PET/CT imaging for treatment response and prognosis in patients with aggressive lymphoma. Eligible patients with histologically confirmed aggressive lymphoma will undergo FAPI PET/CT imaging, and selected patients who are candidates for immunotherapy will undergo Grazytracer PET/CT imaging. These imaging methods are intended to assess fibroblast activation protein expression and granzyme B activity in lymphoma lesions, reflecting cancer-associated fibroblasts and cytotoxic T-cell activity in the tumor microenvironment. The study will explore optimal imaging assessment criteria and develop clinical-pathological-imaging models to predict treatment response, prognosis, and the relationship between tumor heterogeneity and refractory or relapsed disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem chłoniaka agresywnego
- •Wstępne badanie PET/CT pokazujące średnią lub wysoką aktywność w zmianach chłoniaka
- •Brak wcześniejszych nowotworów złośliwych
- •Prawidłowe funkcjonowanie serca, wątroby i nerek
- •Oczekiwana przeżywalność co najmniej 6 miesięcy i możliwość ukończenia obserwacji
✗ Disqualifies
- •Niska aktywność w wstępnym badaniu PET/CT
- •Wszystkie zmiany chłoniaka zostały usunięte chirurgicznie
- •Aktywne lub niekontrolowane zapalenie lub zakażenie
- •Niekontrolowana cukrzyca
- •Brak możliwości leżenia na plecach przez 30 minut
- •Odmowa podpisania zgody na uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Trial contact
Xin Liu, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.